45 results on '"Stein, Mark A."'
Search Results
2. A phase I study of veliparib with cyclophosphamide and veliparib combined with doxorubicin and cyclophosphamide in advanced malignancies.
- Author
-
Tan, Antoinette R., Chan, Nancy, Kiesel, Brian F., Stein, Mark N., Moss, Rebecca A., Malhotra, Jyoti, Aisner, Joseph, Shah, Mansi, Gounder, Murugesan, Lin, Hongxia, Kane, Michael P., Lin, Yong, Ji, Jiuping, Chen, Alice, Beumer, Jan H., and Mehnert, Janice M.
- Subjects
MONONUCLEAR leukocytes ,PACLITAXEL ,METASTATIC breast cancer ,CYCLOPHOSPHAMIDE ,ALKYLATING agents ,ANTHRACYCLINES - Abstract
Purpose: Veliparib (V), an oral poly(ADP-ribose) polymerase (PARP) inhibitor, potentiates effects of alkylating agents and topoisomerase inhibitors in preclinical tumor models. We conducted a phase I trial of V with iv cyclophosphamide (C) and V plus iv doxorubicin (A) and C. Methods: Objectives were to establish the maximum tolerated dose (MTD) of the combinations, characterize V pharmacokinetics (PK) in the presence and absence of C, measure PAR in peripheral blood mononuclear cells (PBMCs) and γH2AX in circulating tumor cells (CTCs). In Group 1, dose escalations of V from 10 to 50 mg every 12 h Days 1–4 plus C 450 to 750 mg/m
2 Day 3 in 21-day cycles were evaluated. In Group 2, V doses ranged from 50 to 150 mg every 12 h Days 1–4 with AC (60/600 mg/m2 ) Day 3 in 21-day cycles. In Group 3, patients received AC Day 1 plus V Days 1–7, and in Group 4, AC Day 1 plus V Days 1–14 was given in 21-day cycles to evaluate effects on γH2AX foci. Results: Eighty patients were enrolled. MTD was not reached for V and C. MTD for V and AC was V 100 mg every 12 h Days 1–4 with AC (60/600 mg/m2) Day 3 every 21 days. V PK appears to be dose-dependent and has no effect on the PK of C. Overall, neutropenia and anemia were the most common adverse events. Objective response in V and AC treated groups was 22% (11/49). Overall clinical benefit rate was 31% (25/80). PAR decreased in PBMCs. Percentage of γH2AX-positive CTCs increased after treatment with V and AC. Conclusion: V and AC can be safely combined. Activity was observed in patients with metastatic breast cancer. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
3. A phase I study of AT-101, a BH3 mimetic, in combination with paclitaxel and carboplatin in solid tumors.
- Author
-
Stein, Mark N., Goodin, Susan, Gounder, Murugeson, Gibbon, Darlene, Moss, Rebecca, Portal, Daniella, Lindquist, Diana, Zhao, Yujie, Takebe, Naoko, Tan, Antoinette, Aisner, Joseph, Lin, Hongxia, Ready, Neal, and Mehnert, Janice M.
- Subjects
ANTINEOPLASTIC agents ,APOPTOSIS ,CANCER chemotherapy ,CLINICAL trials ,DRUG toxicity ,HEALTH outcome assessment ,PACLITAXEL ,PROSTATE tumors ,TIME ,TUMORS ,TREATMENT duration ,DESCRIPTIVE statistics ,CARBOPLATIN ,PHARMACODYNAMICS - Abstract
Summary: Background AT-101 is a BH3 mimetic that inhibits the heterodimerization of Bcl-2, Bcl-xL, Bcl-W, and Mcl-1 with pro-apoptotic proteins, thereby lowering the threshold for apoptosis. This phase I trial investigated the MTD of AT-101 in combination with paclitaxel and carboplatin in patients with advanced solid tumors. Methods Patients were treated with AT-101 (40 mg) every 12 h on days 1, 2 and 3 of each cycle combined with varying dose levels (DL) of paclitaxel and carboplatin [DL1: paclitaxel (150 mg/m
2 ) and carboplatin (AUC 5) on day 1 of each cycle; DL2: paclitaxel (175 mg/m2 ) and carboplatin (AUC 6) on day 1 of each cycle]. Secondary objectives included characterizing toxicity, efficacy, pharmacokinetics, and pharmacodynamics of the combination. Results Twenty-four patients were treated across two DLs with a planned expansion cohort. The most common tumor type was prostate (N = 11). Two patients experienced DLTs: grade 3 abdominal pain at DL1 and grade 3 ALT increase at DL2; however, the MTD was not determined. Moderate hematologic toxicity was observed. One CR was seen in a patient with esophageal cancer and 4 patients achieved PRs (1 NSCLC, 3 prostate). PD studies did not yield statistically significant decreases in Bcl-2 and caspase 3 protein levels, or increased apoptotic activity induced by AT-101. Conclusion The combination of AT-101 at 40 mg every 12 h on days 1, 2 and 3 combined with paclitaxel and carboplatin was safe and tolerable. Based on the modest clinical efficacy seen in this trial, this combination will not be further investigated. Clinical Trial Registration: NCT00891072, CTEP#: 8016. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
4. 18F-Sodium fluoride PET/CT predicts overall survival in patients with advanced genitourinary malignancies treated with cabozantinib and nivolumab with or without ipilimumab.
- Author
-
Lim, Ilhan, Lindenberg, Maria Liza, Mena, Esther, Verdini, Nicholas, Shih, Joanna H., Mayfield, Christian, Thompson, Ryan, Lin, Jeffrey, Vega, Andy, Mallek, Marissa, Cadena, Jacqueline, Diaz, Carlos, Mortazavi, Amir, Knopp, Michael, Wright, Chadwick, Stein, Mark, Pal, Sumanta, Choyke, Peter L., and Apolo, Andrea B.
- Subjects
SODIUM fluoride ,FLUORIDES ,BONE metastasis ,POSITRON emission tomography computed tomography - Abstract
Purpose: We evaluated the prognostic value of
18 F-sodium fluoride (NaF) PET/CT in patients with urological malignancies treated with cabozantinib and nivolumab with or without ipilimumab. Methods: We prospectively recruited patients with advanced urological malignancies into a phase I trial of cabozantinib plus nivolumab with or without ipilimumab. NaF PET/CT scans were performed pre- and 8 weeks post-treatment. We measured the total volume of fluoride avid bone (FTV) using a standardized uptake value (SUV) threshold of 10. We used Kaplan-Meier analysis to predict the overall survival (OS) of patients in terms of SUVmax, FTV, total lesion fluoride (TLF) uptake at baseline and 8 weeks post-treatment, and percent change in FTV and TLF. Result: Of 111 patients who underwent NaF PET/CT, 30 had bone metastases at baseline. Four of the 30 patients survived for the duration of the study period. OS ranged from 0.23 to 34 months (m) (median 6.0 m). The baseline FTV of all 30 patients ranged from 9.6 to 1570 ml (median 439 ml). The FTV 8 weeks post-treatment was 56–6296 ml (median 448 ml) from 19 available patients. Patients with higher TLF at baseline had shorter OS than patients with lower TLF (3.4 vs 14 m; p = 0.022). Patients with higher SUVmax at follow-up had shorter OS than patients with lower SUVmax (5.6 vs 24 m; p = 0.010). However, FTV and TLF 8 weeks post-treatment did not show a significant difference between groups (5.6 vs 17 m; p = 0.49), and the percent changes in FTV (12 vs 14 m; p = 0.49) and TLF (5.6 vs 17 m; p = 0.54) also were not significant. Conclusion: Higher TLF at baseline and higher SUVmax at follow-up NaF PET/CT corresponded with shorter survival in patients with bone metastases from urological malignancies who underwent treatment. NaF PET/CT may be a useful predictor of OS in this population. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
5. Parent ADHD and Evidence-Based Treatment for Their Children: Review and Directions for Future Research.
- Author
-
Chronis-Tuscano, Andrea, Wang, Christine, Woods, Kelsey, Strickland, Jennifer, Stein, Mark, Wang, Christine H, Woods, Kelsey E, and Stein, Mark A
- Subjects
TREATMENT of attention-deficit hyperactivity disorder ,EVIDENCE-based medicine ,CHILD behavior ,PARENTING ,STIMULANTS ,PHARMACOLOGY ,ATTENTION-deficit hyperactivity disorder ,RESEARCH funding ,PROFESSIONAL practice ,CHILDREN of people with mental illness ,PSYCHOLOGY - Abstract
One fourth to one half of parents of children with attention-deficit/hyperactivity disorder (ADHD) have ADHD themselves, complicating delivery of evidence-based child behavioral and pharmacological treatments. In this article, we review the literature examining the relation between parent ADHD and outcomes following behavioral and pharmacological treatments for children with ADHD. We also review research that has incorporated treatment of parent ADHD (either alone or in combination with child treatment) with the goal of improving parenting and child outcomes. Finally, we offer recommendations for future research on the relation between parent ADHD and evidence-based treatment outcomes for their children, with the purpose of advancing the science and informing clinical care of these families. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
6. Targeting Functional Impairments in the Treatment of Children and Adolescents with ADHD.
- Author
-
Sasser, Tyler, Schoenfelder, Erin, Stein, Mark, Schoenfelder, Erin N, and Stein, Mark A
- Subjects
ATTENTION-deficit hyperactivity disorder ,PSYCHIATRIC diagnosis ,TREATMENT of attention-deficit hyperactivity disorder ,DISABILITIES ,JUVENILE diseases ,CLINICAL trials ,PREVENTION ,BEHAVIOR therapy ,HEALTH outcome assessment ,PSYCHOLOGICAL tests ,PSYCHOMETRICS ,DIAGNOSIS - Abstract
The diagnostic criteria for attention-deficit hyperactivity disorder (ADHD) require both symptoms and impairment to be present. Impairment in functioning is commonly the primary reason for referral, and is also a better predictor of long-term outcomes than ADHD symptoms. And yet, only recently has research begun to examine the impact of ADHD treatments on functional impairment using efficient and psychometrically sound outcome measures. In this article, we identify several noteworthy multidimensional measures of functional impairment (ADHD FX, Barkley Functional Impairment Scale [BFIS], Impairment Rating Scale [IRS], Weiss Functional Impairment Rating Scale [WFIRS]) utilized in recent clinical trials for ADHD, and describe their psychometric properties and clinical utility. We also review existing evidence on the impact of pharmacological and behavioral treatments on different domains of functional impairment in ADHD youth as measured by these specific measures. Further research is needed to evaluate longitudinal effects of ADHD treatments on functional impairment, and the use of these measures in adaptive treatment designs. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
7. A phase I trial of MK-2206 and hydroxychloroquine in patients with advanced solid tumors.
- Author
-
Mehnert, Janice M., Kaveney, Amanda D., Malhotra, Jyoti, Spencer, Kristen, Portal, Daniella, Goodin, Susan, Tan, Antoinette R., Aisner, Joseph, Moss, Rebecca A., Lin, Hongxia, Bertino, Joseph R., Gibbon, Darlene, Doyle, Laurence A., White, Eileen P., and Stein, Mark N.
- Subjects
FATIGUE (Physiology) ,TUMORS ,ADVERSE health care events ,HYPERGLYCEMIA - Abstract
Purpose: Given the evidence that coordinate inhibition of AKT induces autophagy, we studied the combination of the AKT inhibitor, MK-2206 with hydroxychloroquine (HCQ) in patients with advanced solid tumors.Methods: Patients were treated with weekly MK-2206 (135 mg or 200 mg) plus HCQ (200 mg, 400 mg or 600 mg BID).Results: Thirty-five patients were enrolled across 5 dose levels. Two DLTs of grade 3 maculo-papular rash were observed at dose level 2 (MK-2206 200 mg weekly plus HCQ at 400 mg BID) and 1 DLT of grade 3 fatigue at dose level 2B (MK-2206 135 mg weekly plus HCQ 600 mg BID). The maximum tolerated dose (MTD) was declared as dose level 2B. The most common adverse events attributed to MK-2206 were hyperglycemia (N = 18; 51%), fatigue (N = 17; 49%), maculo-papular rash (N = 16; 46%), diarrhea (N = 12; 34%), anorexia (N = 11; 31%), and nausea (N = 11; 31%). Patients experiencing adverse events attributed to HCQ were small in number (N = 13) and primarily included fatigue (N = 5; 14%) and maculo-papular rashes (N = 3; 9%). Statistically significant effects on the pharmacokinetic properties of MK-2206 were observed in combination with HCQ. In addition, the plasma concentrations of HCQ in the combination with MK-2206 were significantly higher than the plasma levels of HCQ as monotherapy in prior studies. The best overall response of stable disease was observed in 5/34 (15%) patients.Conclusion: The combination of MK-2206 and hydroxychloroquine was tolerable, but with substantial number of drug-related AEs and minimal evidence of antitumor activity. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
8. Does Guanfacine Extended Release Impact Functional Impairment in Children with Attention-Deficit/Hyperactivity Disorder? Results from a Randomized Controlled Trial.
- Author
-
Stein, Mark, Sikirica, Vanja, Weiss, Margaret, Robertson, Brigitte, Lyne, Andrew, Newcorn, Jeffrey, Stein, Mark A, Weiss, Margaret D, and Newcorn, Jeffrey H
- Subjects
- *
GUANFACINE , *ATTENTION-deficit hyperactivity disorder , *PSYCHIATRIC diagnosis , *SYMPTOMS , *TREATMENT of attention-deficit hyperactivity disorder , *RANDOMIZED controlled trials , *THERAPEUTICS , *COMPARATIVE studies , *CONTROLLED release preparations , *DRUG administration , *DOSE-effect relationship in pharmacology , *ANTIHYPERTENSIVE agents , *RESEARCH methodology , *MEDICAL cooperation , *PHENYLPROPANOLAMINE , *PSYCHOLOGICAL tests , *PSYCHIATRIC drugs , *RESEARCH , *STATISTICAL sampling , *EVALUATION research , *TREATMENT effectiveness , *BLIND experiment - Abstract
Background: In clinical trials of medications to treat attention-deficit/hyperactivity disorder (ADHD) in children, effects on functional impairment have been less well-studied than changes in ADHD symptoms.Objective: Data regarding functional impairment were analyzed from a multicenter, double-blind, placebo-controlled study of guanfacine extended release (GXR) in children with ADHD, using the Weiss Functional Impairment Rating Scale-Parent Report (WFIRS-P). The correspondence of changes in WFIRS-P scores with symptomatic and global response to GXR treatment was also examined, with treatment response defined by scores on both the ADHD Rating Scale IV (ADHD-RS-IV) and the Clinical Global Impressions-Improvement Scale (CGI-I).Methods: In this 8-week, double-blind, placebo-controlled, dose optimization study at 47 sites across the USA and Canada, children aged 6-12 years with a diagnosis of ADHD [Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision criteria, and an ADHD-RS-IV score ≥28 and CGI-Severity of Illness Scale score ≥4 at baseline], were randomized 1:1:1 into three groups: GXR AM [GXR (1-4 mg/day) in the morning, placebo in the evening], GXR PM [placebo in the morning, GXR (1-4 mg/day) in the evening], or twice-daily placebo. Parents rated their children on the WFIRS-P at screening, baseline, the end of dose optimization, and at the final on-treatment assessment.Results: The efficacy population was composed of 333 subjects (GXR AM: n = 107; GXR PM: n = 114; placebo: n = 112). At the final on-treatment assessment, there were significant improvements from baseline in the placebo-adjusted difference in least-squares (LS) mean (95 % confidence interval) WFIRS-P Total scores for both GXR treatment groups combined [GXR all-active: -0.16 (-0.25, -0.07), effect size (ES) = 0.448, P <0.001] and separately [GXR AM: -0.15 (-0.26, -0.05), ES = 0.417, P = 0.004; GXR PM: -0.18 (-0.28, -0.07), ES = 0.478, P = 0.001]. Significant improvements in WFIRS-P domain scores for Family, Learning and School (including Academic Performance and Behavior in School), Social, and Risky Behavior were found for both GXR cohorts compared with placebo. However, the Life Skills and Self-Concept domain scores of the WFIRS-P did not improve with GXR treatment. Post hoc stratification by responder status revealed that significant (P <0.001) improvements in WFIRS-P Total and all domain scores were associated with symptomatic treatment response in the GXR all-active group.Conclusions: GXR treatment in children with ADHD was associated with reductions in WFIRS-P functional impairment scores compared with placebo, regardless of time of GXR administration. Changes in WFIRS-P scores were congruent with clinical response, as determined by both ADHD symptom reduction and CGI-I scores. CLINICALTRIALS.Gov Identifier: NCT00997984. [ABSTRACT FROM AUTHOR]- Published
- 2015
- Full Text
- View/download PDF
9. Apatorsen plus docetaxel versus docetaxel alone in platinum-resistant metastatic urothelial carcinoma (Borealis-2).
- Author
-
Rosenberg, Jonathan E., Hahn, Noah M., Regan, Meredith M., Werner, Lillian, Alva, Ajjai, George, Saby, Picus, Joel, Alter, Robert, Balar, Arjun, Hoffman-Censits, Jean, Grivas, Petros, Lauer, Richard, Guancial, Elizabeth A., Hoimes, Christopher, Sonpavde, Guru, Albany, Constantine, Stein, Mark N., Breen, Tim, Jacobs, Cindy, and Anderson, Kirsten
- Abstract
Background: A randomised study to assess the addition of apatorsen, an antisense oligonucleotide that inhibits Hsp27 expression, to docetaxel in patients with metastatic urothelial carcinoma (mUC) relapsed after prior platinum-based chemotherapy.Methods: Multicentre, phase II study with 1:1 randomisation to apatorsen (three loading doses at 600 mg intravenous followed by weekly doses) plus docetaxel (75 mg/m2 intravenous every 21 days) (A/D) or docetaxel alone. Overall survival (OS) was the primary end point with a P value <0.1 (one-sided) being positive. Progression-free survival (PFS), objective response rate (ORR), safety, and effect of Hsp27 levels on outcomes were secondary end points.Results: Patients randomised to A/D (n = 99) had improved OS compared to docetaxel alone (n = 101): HR: 0.80, 80% CI: 0.65-0.98, P = 0.0784, median 6.4 vs 5.9 months. PFS and ORR were similar in both arms. A/D had more incidence of sepsis and urinary tract infections. Patients with baseline Hsp27 levels <5.7 ng/mL had improved OS compared to those with levels ≥5.7 ng/mL. Patients with a decline or ≤20.5% increase in Hsp27 from baseline benefited more from A/D than those with >20.5% increase.Conclusions: A/D met its predefined OS end point in patients with platinum-refractory mUC in this phase II trial. This trial is hypothesis generating requiring further study before informing practice. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
10. A phase I dose-escalation study of the safety and pharmacokinetics of a tablet formulation of voxtalisib, a phosphoinositide 3-kinase inhibitor, in patients with solid tumors.
- Author
-
Mehnert, Janice M., Edelman, Gerald, Stein, Mark, Camisa, Heather, Lager, Joanne, Dedieu, Jean-François, Ghuysen, Anne-Frédérique, Sharma, Jyoti, Liu, Li, and LoRusso, Patricia M.
- Subjects
ANTINEOPLASTIC agents ,CLINICAL trials ,DRUG dosage ,DOSAGE forms of drugs ,CLINICAL drug trials ,DRUG toxicity ,GENETIC techniques ,PATIENT safety ,PHARMACEUTICAL arithmetic ,DRUG tablets ,TUMORS ,PROTEIN kinase inhibitors - Abstract
Background Voxtalisib, a PI3K/mTOR inhibitor, has shown antitumor activity in capsule formulation in patients with solid tumors. This Phase I study assessed safety and pharmacokinetics of voxtalisib administered as immediate-release tablets in patients with solid tumors (NCT01596270).Methods A “3 + 3” dose escalation design was used. Adverse events (AEs), pharmacokinetics (PK), food effect and tumor response were evaluated.Results Thirty-two patients received voxtalisib doses ranging from 50 mg to 70 mg once daily (QD) and 17 patients received voxtalisib doses ranging from 30 mg to 50 mg twice daily (BID), for two 28-day cycles. Dose-limiting toxicities (DLTs) were Grade 3 fatigue (two patients at 70 mg QD, one patient at 40 mg BID) and Grade 3 rash (two patients at 50 mg BID). The maximum tolerated dose (MTD) was 60 mg for QD and 40 mg for BID regimens. Common treatment-emergent AEs were diarrhea (41%), nausea (37%) and fatigue (33%). Voxtalisib appeared to follow linear PK, with a general increase in plasma exposure with dose and no significant accumulation. Administration with food caused a slight decrease in exposure; however, given the high variability observed in the exposure parameters, this should be interpreted with caution. Best response was stable disease in 29% and 50% of patients (QD and BID regimens, respectively).Conclusions The safety profile of voxtalisib tablets at the MTD in patients with solid tumors was consistent with that observed with voxtalisib capsules. Given the limited activity observed across multiple clinical trials, no further trials of voxtalisib are planned. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
11. Dose-Response Effects of Long-Acting Liquid Methylphenidate in Children with Attention Deficit/Hyperactivity Disorder (ADHD) and Autism Spectrum Disorder (ASD): A Pilot Study.
- Author
-
Kim, Soo-Jeong, Shonka, Sophia, French, William, Strickland, Jennifer, Miller, Lindsey, and Stein, Mark
- Subjects
ATTENTION-deficit hyperactivity disorder ,AUTISM ,DOSE-effect relationship in pharmacology ,METHYLPHENIDATE ,STATISTICAL sampling ,PILOT projects ,CHILDREN - Abstract
Attention deficit/hyperactivity disorder (ADHD) symptoms are common in youth with autism spectrum disorders (ASD) and are frequently treated with stimulant medications. Twenty-seven children were randomized to different dose titration schedules, and ADHD symptoms, tolerability, and aberrant behaviors were assessed weekly during a 6-week trial with long-acting liquid methylphenidate (MPH). MPH at low to moderate doses was effective in reducing ADHD symptoms and was well tolerated in young children with ASD and ADHD. Future studies are needed to assess generalization and maintenance of efficacy. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
12. Evaluation of the Safety, Tolerability, and Pharmacokinetics of Gammaplex 10% Versus Gammaplex 5% in Subjects with Primary Immunodeficiency.
- Author
-
Wasserman, Richard, Melamed, Isaac, Stein, Mark, Jolles, Stephen, Norton, Miranda, and Moy, James
- Subjects
PHARMACOKINETICS ,INTRAVENOUS immunoglobulins ,IMMUNODEFICIENCY ,IMMUNOGLOBULIN G ,PELVIC inflammatory disease treatment ,DIAGNOSIS ,THERAPEUTICS - Abstract
Purpose: This phase 3, multicenter, open-label, randomized, two-period, crossover bioequivalence trial evaluated the safety, tolerability, and pharmacokinetics of intravenous immunoglobulins (IVIGs) Gammaplex 5% and Gammaplex 10% in 33 adults and 15 children with primary immunodeficiency diseases (PIDs). Methods: Eligible adults received five Gammaplex 5% infusions followed by five Gammaplex 10% infusions, or vice versa, stratified by a 21- or 28-day dosing regimen. Pediatric subjects received five Gammaplex 10% infusions only. Results: The primary objective, to demonstrate the bioequivalence of Gammaplex 10% and Gammaplex 5% at the 28-day dosing interval, was met based on the Gammaplex 10%/Gammaplex 5% ratio of area under the concentration versus time curve (AUC) values. Throughout the study, total immunoglobulin G trough levels were well maintained, with total values generally ≥600 mg/dL (minimum level for study inclusion). At the dosing schedules and infusion rates used in this study, safety and tolerability were comparable and acceptable in adult and pediatric PID subjects treated with Gammaplex 10% and 5%. Conclusions: In this study, the first direct comparison of 5% IVIG and 10% IVIG products in PID subjects, the pharmacokinetic analysis demonstrated bioequivalence of Gammaplex 10% and Gammaplex 5% at the 28-day dosing interval. The Gammaplex 10% formulation was safe and well tolerated in pediatric and adult PID subjects. Based on the results from this bridging study in PID subjects, Gammaplex 10% could be expected to have a therapeutic effect similar to the licensed Gammaplex 5%, which has demonstrated efficacy and tolerability in patients with PID and idiopathic thrombocytopenic purpura. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
13. Efficacy, Safety, and Pharmacokinetics of a Novel Human Immune Globulin Subcutaneous, 20 % in Patients with Primary Immunodeficiency Diseases in North America.
- Author
-
Suez, Daniel, Stein, Mark, Gupta, Sudhir, Hussain, Iftikhar, Melamed, Isaac, Paris, Kenneth, Darter, Amy, Bourgeois, Christelle, Fritsch, Sandor, Leibl, Heinz, McCoy, Barbara, Gelmont, David, and Yel, Leman
- Subjects
- *
IMMUNOLOGICAL deficiency syndrome treatment , *INTRAVENOUS immunoglobulins , *PHARMACOKINETICS , *IMMUNOLOGICAL deficiency syndromes , *DRUG efficacy , *MEDICATION safety , *PATIENTS - Abstract
Patients with primary immunodeficiency disease (PIDD) typically require life-long intravenous (IV) or subcutaneous (SC) immunoglobulin (Ig) replacement therapy to prevent recurrent infections. The efficacy, safety, and pharmacokinetics of a highly concentrated (20 %) Ig preparation for SC administration (IGSC 20 %) were evaluated in a prospective trial in patients with PIDD. A total of 74 patients (aged 3-83 years) received 4327 IGSC 20 % infusions over a median of 380.5 days. The rate of validated serious bacterial infections was 0.012 event/patient-year ( p < 0.0001 compared with the historical control), and the annualized rate of infection was 2.41 events/patient. Median IgG trough levels were >14.5 g/l. The median maximum infusion rate was 60 ml/h/site (range 4.4-180), resulting in a median infusion duration of 0.95 h. A volume ≥30 ml was infused per site in 74.8 % of IGSC 20 % infusions. Most (84.9 %) infusions were administered using ≤2 infusion sites; for 99.8 % of infusions, there was no need to interrupt/stop administration or reduce the infusion rate. No related serious adverse event (AE) occurred during IGSC 20 % treatment; related non-serious AEs occurred at a rate of 0.036 event/infusion. The incidence of related local AEs was 0.015 event/infusion and of related systemic AEs was 0.021 event/infusion; most were mild in severity, none severe. Increased infusion rates or volumes were not associated with higher AE rates. The investigated IGSC 20 % treatment was shown to be effective and safe, enabling higher infusion rates and volumes per site compared to conventional SC treatments, resulting in fewer infusion sites and shorter infusion durations. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
14. Efficacy, Safety, and Pharmacokinetics of a New 10 % Liquid Intravenous Immunoglobulin Containing High Titer Neutralizing Antibody to RSV and Other Respiratory Viruses in Subjects with Primary Immunodeficiency Disease.
- Author
-
Wasserman, Richard, Lumry, William, Harris, James, Levy, Robyn, Stein, Mark, Forbes, Lisa, Cunningham-Rundles, Charlotte, Melamed, Isaac, Kobayashi, Ai, Du, Wei, and Kobayashi, Roger
- Subjects
IMMUNODEFICIENCY ,IMMUNOGLOBULINS ,PHARMACOKINETICS ,DRUG efficacy ,MEDICATION safety ,CLINICAL trials ,HOSPITAL care ,THERAPEUTICS - Abstract
Purpose: Immune globulins for IgG supplementation have been produced for over 35 years with essentially no differentiating features regarding their specific antibody composition. Furthermore, the compositions of plasma donor pools used for IG manufacturing are not standardized. While all immune globulin products meet the specifications set by the US FDA for antibodies to pathogens like measles and polio, they have variable levels of antibodies to other important viruses and infectious pathogens, particularly respiratory syncytial virus (RSV). Methods: An IVIG was developed that satisfies the requirements for treating patients with primary immune deficiency disease (PIDD) and also has standardized elevated levels of RSV neutralizing antibodies (RI-002). Plasma donors who have naturally occurring high circulating levels of neutralizing anti-RSV antibody were selected as the source for manufacturing IVIG to treat patients with PIDD to prevent serious bacterial infections. While the introduction of the monoclonal antibody Palivizumab has had a dramatic impact in diminishing the burden of RSV disease in the pediatric population, it does not meet the standards for replacing the deficient immune compartments of patients with PIDD. Results: Fifty-nine patients with PIDD at 9 different sites across the US were enrolled in this study and received regular infusions of RI-002 over the course of 1 year. Conclusions: There were zero serious bacterial infections, thus meeting the primary endpoint for this trial. The secondary endpoints including days missed from work due to infection, unscheduled visits to the physician, and days of hospitalization due to infection compared favorably to published reports of other IVIG products. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
15. Long-Term Tolerability, Safety, and Efficacy of Recombinant Human Hyaluronidase-Facilitated Subcutaneous Infusion of Human Immunoglobulin for Primary Immunodeficiency.
- Author
-
Wasserman, Richard, Melamed, Isaac, Stein, Mark, Engl, Werner, Sharkhawy, Marlies, Leibl, Heinz, Puck, Jennifer, Rubinstein, Arye, Kobrynski, Lisa, Gupta, Sudhir, Grant, Andrew, Ratnayake, Anoshie, Richmond, Wendell, Church, Joseph, Yel, Leman, and Gelmont, David
- Subjects
IMMUNODEFICIENCY ,HYALURONIDASES ,THERAPEUTIC use of immunoglobulins ,SUBCUTANEOUS infusions ,MEDICATION safety ,DRUG efficacy ,THERAPEUTICS - Abstract
Purpose: Treatment of primary immunodeficiency diseases (PIDD) with subcutaneous (SC) infusions of IgG preceded by injection of recombinant human hyaluronidase (rHuPH20) (IGHy) to increase SC tissue permeability was evaluated in two consecutive, prospective, non-controlled, multi-center studies. Methods: Subjects >4 years of age received SC IgG replacement at a weekly dose equivalent of 108 % of their previous intravenous (IV) dose, facilitated by prior injection of 75 U/g IgG of rHuPH20. Starting with weekly SC infusions, the interval was increased (ramped-up) to a 3- or 4-week schedule. Results: Eighty-three subjects (24 < 18 years; 59 ≥ 18 years) received 2729 infusions (excluding ramp-up) at a mean dose of 0.155 g/kg/week in the pivotal and 0.156 g/kg/week in the extension study. IGHy exposure exceeded 30 months in 48 subjects. During 187.7 subject-years of IGHy exposure, 2005 adverse events (AEs) (10.68 per subject-year) occurred. The rate of related systemic AEs during consecutive 1-year periods remained low; the rate of related local AEs decreased from 3.68/subject-year in months 1-12 to approximately 1.50/subject-year after 30 months of treatment. Fifteen subjects transiently developed anti-rHuPH20 binding antibody. There was no difference in AE rates in these subjects before and after the first titer increase to ≥1:160. The rate of infections during IGHy exposure was 2.99 per subject-year and did not increase during the studies. Annual infection rates were 3.02 in subjects <18 years and 2.98 in subjects ≥18 years. Conclusions: Long-term replacement therapy with IGHy was safe and effective in 83 pediatric and adult subjects with PIDD. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
16. A phase I study of MK-5108, an oral aurora a kinase inhibitor, administered both as monotherapy and in combination with docetaxel, in patients with advanced or refractory solid tumors.
- Author
-
Amin, Manik, Minton, Susan, LoRusso, Patricia, Krishnamurthi, Smitha, Pickett, Cheryl, Lunceford, Jared, Hille, Darcy, Mauro, David, Stein, Mark, Wang-Gillam, Andrea, Trull, Lauren, and Lockhart, A.
- Published
- 2016
- Full Text
- View/download PDF
17. A phase II trial of ganetespib, a heat shock protein 90 Hsp90) inhibitor, in patients with docetaxel-pretreated metastatic castrate-resistant prostate cancer (CRPC)-a prostate cancer clinical trials consortium (PCCTC) study.
- Author
-
Thakur, Manish, Heilbrun, Lance, Sheng, Shijie, Stein, Mark, Liu, Glenn, Antonarakis, Emmanuel, Vaishampayan, Ulka, Dzinic, Sijana, Li, Xiaohua, Freeman, Stacy, Smith, Daryn, and Heath, Elisabeth
- Published
- 2016
- Full Text
- View/download PDF
18. New Research on the Complex Interaction of Sleep and ADHD.
- Author
-
Weiss, Margaret, Craig, Stephanie, Davies, Gregory, Schibuk, Larry, and Stein, Mark
- Published
- 2015
- Full Text
- View/download PDF
19. A phase I pharmacodynamic trial of sequential sunitinib with bevacizumab in patients with renal cell carcinoma and other advanced solid malignancies.
- Author
-
Bruce, Justine, Kolesar, Jill, Hammers, Hans, Stein, Mark, Carmichael, Lakeesha, Eickhoff, Jens, Johnston, Susan, Binger, Kimberly, Heideman, Jennifer, Perlman, Scott, Jeraj, Robert, and Liu, Glenn
- Subjects
PHARMACODYNAMICS ,INDOLE ,BEVACIZUMAB ,RENAL cell carcinoma ,VASCULAR endothelial growth factors ,THROMBOTIC thrombocytopenic purpura ,PHARMACOKINETICS ,PATIENTS ,THERAPEUTICS - Abstract
Background: Sunitinib treatment results in a compensatory increase in plasma VEGF levels. Acute withdrawal of sunitinib results in a proliferative withdrawal flare, primarily due to elevated VEGF levels. Concurrent sunitinib plus bevacizumab is poorly tolerated with high (37 %) incidence of microangiopathic hemolytic anemia (MAHA). We evaluated a sequential design administering bevacizumab during the sunitinib treatment break to suppress the sunitinib withdrawal flare. Methods: Patients with no prior VEGF treatment were enrolled in this study. All patients had target lesions amenable to serial FLT PET/CT imaging. Sunitinib 37.5 mg was given on days 1-28 every 6 weeks with bevacizumab 5 mg/kg on day 29. If safe and tolerable, sunitinib increased to 50 mg. FLT PET/CT scans would be obtained at baseline (D1), week 4, and week 6 to evaluate pharmacodynamics of the sequential combination. Sunitinib pharmacokinetics and total, free, and bound VEGF levels were obtained on each cycle at D1, pre-bevacizumab (D29), 4 h post-bevacizumab (D29H4), and day 42 (D42). Results: Six patients enrolled in the safety cohort of sunitinib 37.5 mg plus bevacizumab (see Table). One patient experienced grade 1 MAHA, and after discussion with the Cancer Therapy Evaluation Program (CTEP), the trial was closed to further accrual. No imaging scans were obtained due to early closure. Conclusions: Subclinical MAHA was seen despite using sequential sunitinib with low-dose bevacizumab, and this combination was not feasible for further development. As predicted, VEGF levels increased during sunitinib exposure followed by a rapid decline after bevacizumab. Due to the long half-life of bevacizumab, we expected VEGF ligand suppression through D42, but instead observed a complete rebound in total/free VEGF levels by D42. The increase in VEGF at D42 was unexpected based on sunitinib alone and contrary to the hypothesis that we would block VEGF flare with low-dose bevacizumab. VEGF ligand production may increase as a result of bevacizumab, implying a robust host compensatory mechanism to VEGF signaling pathway inhibition. A greater understanding of the compensatory mechanism would aid future sequencing strategies of new agents. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
20. Effects of ketoconazole and esomeprazole on the pharmacokinetics of pazopanib in patients with solid tumors.
- Author
-
Tan, Antoinette, Gibbon, Darlene, Stein, Mark, Lindquist, Diana, Edenfield, Jeffery, Martin, Julie, Gregory, Charles, Suttle, A., Tada, Hiroomi, Botbyl, Jeffrey, and Stephenson, Joseph
- Subjects
TUMORS ,KETOCONAZOLE ,ESOMEPRAZOLE ,PHARMACOKINETICS ,HYDROGEN-ion concentration ,PROTON pump inhibitors ,METABOLITES ,PATIENTS - Abstract
Purpose: The metabolism of pazopanib is primarily mediated by CYP3A4. The solubility of pazopanib is pH-dependent, and an elevated gastric pH may decrease its bioavailability. This study evaluated the effect of a potent CYP3A4 inhibitor, ketoconazole, and the proton pump inhibitor esomeprazole on the pharmacokinetics and safety of pazopanib and its metabolites. Methods: In Arm A, patients received pazopanib 400 mg alone once daily for 7 days followed by pazopanib 400 mg plus ketoconazole 400 mg once daily for 5 days. In Arm B, patients received pazopanib 800 mg once daily for 7 days, followed by pazopanib 800 mg plus esomeprazole 40 mg once daily for 5 days, and then pazopanib alone on the last day. Results: Arm A enrolled 21 patients. In the presence of ketoconazole, mean area under the plasma concentration-time curve 24 h post-dose (AUC) and mean maximum observed concentration ( C) of pazopanib increased by 66 and 45 %, respectively; mean AUC and C for pazopanib metabolites were lower or remained unchanged. Arm B enrolled 13 patients. In the presence of esomeprazole, mean pazopanib AUC and C decreased by 40 and 42 %, respectively; mean values of those parameters for metabolites of pazopanib also decreased. Conclusions: Concomitant use of pazopanib with a strong CYP3A4 inhibitor should be avoided. If coadministration is necessary, pazopanib should be reduced to 400 mg. Concomitant use of pazopanib and proton pump inhibitors should also be avoided. Alternative dosing regimens that do not increase gastric pH at the time of pazopanib dosing should be considered. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
21. A phase I dose-escalation trial of 2-deoxy- d-glucose alone or combined with docetaxel in patients with advanced solid tumors.
- Author
-
Raez, Luis, Papadopoulos, Kyriakos, Ricart, Alejandro, Chiorean, E., DiPaola, Robert, Stein, Mark, Rocha Lima, Caio, Schlesselman, James, Tolba, Khaled, Langmuir, Virginia, Kroll, Stewart, Jung, Donald, Kurtoglu, Metin, Rosenblatt, Joseph, and Lampidis, Theodore
- Subjects
CANCER patients ,DRUG dosage ,DOCETAXEL ,CLINICAL trials ,PHARMACOKINETICS ,INTRAVENOUS therapy - Abstract
Purpose: This phase I trial was initiated to evaluate the safety, pharmacokinetics (PK) and maximum tolerated dose (MTD) of the glycolytic inhibitor, 2-deoxy- d-glucose (2DG) in combination with docetaxel, in patients with advanced solid tumors. Methods: A modified accelerated titration design was used. 2DG was administered orally once daily for 7 days every other week starting at a dose of 2 mg/kg and docetaxel was administered intravenously at 30 mg/m for 3 of every 4 weeks beginning on day 1 of week 2. Following the completion of dose escalation, cohorts of patients were then treated with 2DG for 21 days or every day of each 4-week cycle for up to 12 cycles. Results: Thirty-four patients were enrolled: 21 on every other week, 6 on a 21 of 28-day cycle and 7 on the continuous 2DG dosing schedule. There were no dose-limiting toxicities which met the MTD criteria. The most common adverse events were fatigue, sweating, dizziness and nausea mimicking the hypoglycemic symptoms expected from 2DG administration. Therefore, 63 mg/kg was selected as the clinically tolerable dose. The most significant adverse effects noted at 63-88 mg/kg doses were reversible hyperglycemia (100 %), gastrointestinal bleeding (6 %) and reversible grade 3 QTc prolongation (22 %). Eleven patients (32 %) had stable disease, 1 patient (3 %) partial response and 22 patients (66 %) progressive disease as their best response. There was no PK interaction between 2DG and docetaxel. Conclusion: The recommended dose of 2DG in combination with weekly docetaxel is 63 mg/kg/day with tolerable adverse effects. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
22. Pharmacotherapy for Parents with Attention-Deficit Hyperactivity Disorder (ADHD) Impact on Maternal ADHD and Parenting.
- Author
-
Chronis-Tuscano, Andrea and Stein, Mark A.
- Subjects
- *
TREATMENT of attention-deficit hyperactivity disorder , *PARENTING , *CHILDREN with attention-deficit hyperactivity disorder , *DRUG therapy , *HERITABILITY , *PARENT-child communication , *TREATMENT effectiveness - Abstract
Given the high heritability of the disorder, attention-deficit hyperactivity disorder (ADHD) is common among parents of children with ADHD. Parental ADHD is associated with maladaptive parenting, negative parent-child interaction patterns and a diminished response to behavioural parent training. We describe our previous research demonstrating that stimulant medications for mothers with ADHD are associated with reductions in maternal ADHD symptoms. Although limited beneficial effects on self-reported parenting were also found in our study, the impact of ADHD medications on functional outcomes related to parenting and family interactions may not be sufficient for many families. Many questions remain with regard to how best to treat multiplex ADHD families in which a parent and child have ADHD. In particular, future studies are needed: (1) to evaluate how best to sequence pharmacotherapy, psychosocial treatment for adult ADHD and behavioural parenting interventions; (2) to determine the best approach to maintaining treatment effects over the long term for both parents and children; and (3) to identify individual predictors of treatment response. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
23. Safety, Efficacy and Pharmacokinetics of a New 10% Liquid Intravenous Immunoglobulin (IVIG) in Patients with Primary Immunodeficiency.
- Author
-
Wasserman, Richard, Church, Joseph, Stein, Mark, Moy, James, White, Martha, Strausbaugh, Steven, Schroeder, Harry, Ballow, Mark, Harris, James, Melamed, Isaac, Elkayam, David, Lumry, William, Suez, Daniel, and Rehman, Syed
- Subjects
IMMUNOGLOBULINS ,PHARMACOKINETICS ,DRUG efficacy ,MEDICATION safety ,IMMUNODEFICIENCY ,INTRAVENOUS drug abuse ,CLINICAL trials - Abstract
Introduction: An investigational 10% liquid intravenous immunoglobulin (IVIG) was studied in 63 patients with primary immunodeficiency (PID) at 15 study sites. Methods: Patients were treated every 3 or 4 weeks with 254-1029 mg/kg/infusion of IVIG. Results: Overall, Biotest-IVIG infusions were well tolerated. The proportion of infusions that were associated with adverse events during infusion, and up to 72 h after infusion, including those unrelated to study product, was 27.7% with an upper 95% confidence limit ≤30.6%. Two serious bacterial infections (SBIs) were observed resulting in a serious bacterial infection rate of 0.035 per person per year and an upper one-sided 99% confidence limit of ≤0.136 SBI/patient/year. The number of days of work or school missed due to infection were relatively low at 2.28 days/patient/year. Two patients were hospitalized for infection producing a rate of 0.21 hospitalization days/patient/year. The IgG half-life was approximately 30 days with variation among individuals. Conclusions: Pharmacokinetic parameters of specific antibody activities were essentially the same as those of total IgG. Biotest-IVIG is safe and effective in the treatment of PID. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
24. A phase I trial of MK-0731, a Kinesin Spindle Protein (KSP) inhibitor, in patients with solid tumors.
- Author
-
Holen, Kyle, DiPaola, Robert, Liu, Glenn, Tan, Antoinette, Wilding, George, Hsu, Karl, Agrawal, Nancy, Chen, Cong, Xue, Lingling, Rosenberg, Elizabeth, and Stein, Mark
- Published
- 2012
- Full Text
- View/download PDF
25. Phase I study of gemcitabine, docetaxel and imatinib in refractory and relapsed solid tumors.
- Author
-
Saraiya, Biren, Chugh, Rashmi, Karantza, Vassiliki, Mehnert, Janice, Moss, Rebecca, Savkina, Nelli, Stein, Mark, Baker, Laurence, Chenevert, Thomas, and Poplin, Elizabeth
- Published
- 2012
- Full Text
- View/download PDF
26. Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: a randomized phase II trial by the prostate cancer clinical trials consortium.
- Author
-
Bradley, Deborah, Daignault, Stephanie, Ryan, Charles, DiPaola, Robert, Smith, David, Small, Eric, Gross, Mitchell, Stein, Mark, Chen, Alice, and Hussain, Maha
- Published
- 2011
- Full Text
- View/download PDF
27. Pharmacokinetics of Subcutaneous IgPro20 in Patients with Primary Immunodeficiency.
- Author
-
Wasserman, Richard L., Melamed, Isaac, Nelson Jr., Robert P., Knutsen, Alan P., Fasano, Mary Beth, Stein, Mark R., Rojavin, Mikhail A., and Church, Joseph A.
- Subjects
IMMUNOGLOBULINS ,PHARMACOKINETICS ,IMMUNODEFICIENCY ,DRUG dosage ,INTRAVENOUS therapy ,LONGITUDINAL method ,CLINICAL trials ,PATIENTS - Abstract
Background and Objectives: Immunoglobulin replacement is a standard therapy for patients with primary immunodeficiencies. Subcutaneous administration of immunoglobulin offers more constant IgG levels than intravenous administration and simplifies administration for some patients. Use of L-proline as an excipient contributes to the stability of highly concentrated IgG preparations. The aims of the present study were to evaluate the pharmacokinetics of IgPro20 (Hizentra®), a new 20% subcutaneous IgG solution, and compare the area under the serum concentration-time curve (AUC) with that of a similar intravenous 10% IgG solution (IgPro10; Privigen®). At the request of the US FDA, an algorithm for determining IgG trough level ratios (TLRs) was developed in order to provide physicians with a practical tool for monitoring doses during steady-state IgPro20 therapy. Methods: This was a prospective, open-label, multicentre, single-arm, phase III clinical trial conducted in the US. The study was performed in a primary-care setting. Eligible patients were males or females aged 6-75 years with a primary immunodeficiency (common variable immunodeficiency or X-linked agamma-globulinaemia) who had received regular treatment with IgPro10 for at least 3 months prior to entering this study and had achieved serum trough concentration (C
trough ) values ≥>5 g/L. IgPro20 was administered subcutaneously once weekly at initial doses equivalent to 130% of patients' previous doses, based on the results obtained in a Vivaglobin® study and due to an FDA request. After run-in, each patient's dose was adjusted to achieve an AUC comparable to that achieved with IgPro10 administered intravenously. Results: Eighteen patients completed the study. Mean IgPro20:IgPro10 dose ratio (dose adjustment co-efficient) was 1.53 (range 1.26-1.87). The resulting mean AUCs were 105.6g · day/L for IgPro20 versus 103.2 g · day/L for IgPro10 (geometric mean ratio 1.002; lower one-sided 95% confidence limit [CL] 0.951). Thus, the primary endpoint of the study was met, as this result exceeded the pre-specified criterion of the lower one-sided 95% CL of ≥0.8 for non-inferiority. At these AUCs, which were considered equivalent, the mean IgPro20 : IgPro10 TLR, determined by the developed algorithm, was 1.29 (range 1.18-1.73). Titres of specific antibodies tested were well above respective product specifications, suggesting that protection against infection would be effective. Conclusion: Steady-state AUCs with subcutaneous IgPro20 and intravenous IgPro10 were equivalent. Mean dose adjustment coefficient and mean TLR can be used for initial dose conversion without risk of under- protection but vary too widely to be considered measures of equivalence. Trial registration number (clinicaltrials.gov): NCT00419341 [ABSTRACT FROM AUTHOR]- Published
- 2011
- Full Text
- View/download PDF
28. Efficacy, Safety, and Pharmacokinetics of a 10% Liquid Immune Globulin Preparation (GAMMAGARD LIQUID, 10%) Administered Subcutaneously in Subjects with Primary Immunodeficiency Disease.
- Author
-
Wasserman, Richard, Melamed, Isaac, Kobrynski, Lisa, Strausbaugh, Steven, Stein, Mark, Sharkhawy, Marlies, Engl, Werner, Leibl, Heinz, Sobolevsky, Luba, Gelmont, David, Schiff, Richard, and Grossman, William
- Subjects
PHARMACOKINETICS ,IMMUNODEFICIENCY ,IMMUNOGLOBULIN G ,BACTERIAL diseases ,SUBCUTANEOUS surgery ,INTRAVENOUS therapy ,CLINICAL immunology - Abstract
multi-center, prospective, open-label study was conducted in primary immunodeficiency disease patients to determine the tolerability and pharmacokinetics of a 10% liquid IgG preparation administered subcutaneously. Forty-nine subjects (3-77 years old) were enrolled. Pharmacokinetic equivalence of subcutaneous treatment was achieved at a median dose of 137% of the intravenous dose, with a mean trough IgG level of 1,202 mg/dL at the end of the assessment period. The overall infection rate during subcutaneous treatment was 4.1 per subject-year. Three acute serious bacterial infections were reported, resulting in a rate of 0.067 per subject-year. A low overall rate of temporally associated adverse events (8%), and a very low rate of infusion site adverse events (2.8%), was seen at volumes up to 30 mL/site and rates ≤30 mL/h/site. Thus, subcutaneous replacement therapy with a 10% IgG preparation proved effective, safe and well-tolerated in our study population of subjects with primary immunodeficiency disease. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
29. Tolerability of a New 10% Liquid Immunoglobulin for Intravenous Use, Privigen®, at Different Infusion Rates.
- Author
-
Sleasman, John W., Duff, Carla M., Dunaway, Theresa, Rojavin, Mikhail A., and Stein, Mark R.
- Subjects
PROLINE ,IMMUNOGLOBULINS ,GLOBULINS ,IMMUNODEFICIENCY ,IMMUNITY - Abstract
The tolerability of L-proline-stabilized Privigen®, a new 10% liquid immunoglobulin for intravenous administration, was assessed at high infusion rates in a Phase III, open-label, single-arm, multicenter study in 45 patients with primary immune deficiencies. Maximum infusion rates were not assigned prospectively. For analysis, patients were grouped according to maximum infusion rate in a low infusion rate group (8 mg/kg/min) and high infusion rate group (12 mg/kg/min). Twenty-three patients, selected at the investigators’ discretion for the high infusion rate group based on their good tolerability, tolerated Privigen® at 12 mg/kg/min with no increase in temporally associated adverse events (AEs) above the level they had experienced at 8 mg/kg/min. The proportion of infusions with temporally associated AEs in these patients was 0.079 [97.5% confidence interval (CI) 0.114] compared to 0.211 (97.5% CI 0.267) in the low infusion rate group. The most frequent AE was headache. Thus, selected patients tolerate Privigen® at high infusion rates. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
30. Efficacy, Pharmacokinetics, Safety, and Tolerability of Flebogamma® 10% DIF, a High-Purity Human Intravenous Immunoglobulin, in Primary Immunodeficiency.
- Author
-
Berger, Melvin, Pinciaro, Paul J., Althaus, Arthur, Ballow, Mark, Chouksey, Akhilesh, Moy, James, Ochs, Hans, and Stein, Mark
- Subjects
IMMUNOGLOBULIN G ,PHARMACOKINETICS ,IMMUNODEFICIENCY ,CLINICAL trials ,NANOFILTRATION - Abstract
Flebogamma® 10% DIF represents an evolution of intravenous immune globulin from the previous 5% product to be administered at higher rates and with smaller infusion volumes. Pathogen safety is enhanced by the combination of multiple methods with different mechanisms of action. The objective of this study as to evaluate the efficacy, pharmacokinetics, and safety of Flebogamma® 10% DIF for immunoglobulin replacement therapy in primary immunodeficiency diseases (PIDD). Flebogamma® 10% DIF was administered to 46 subjects with well-defined PIDD at a dose of 300–600 mg/kg every 21–28 days for 12 months. Serious bacterial infection rate was 0.025/subject/year. Half-life in serum of the administered IgG was approximately 35 days. No serious treatment-related adverse event (AE) occurred in any patient. Most of the potentially treatment-related AEs occurred during the infusion, accounting for 20% of the 601 infusions administered. Flebogamma® 10% DIF is efficacious and safe, has adequate pharmacokinetic properties, and is well-tolerated for the treatment of PIDD. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
31. Progress and Promise of Attention-Deficit Hyperactivity Disorder Pharmacogenetics.
- Author
-
Froehlich, Tanya E., McGough, James J., and Stein, Mark A.
- Subjects
ATTENTION-deficit hyperactivity disorder ,BEHAVIOR disorders in children ,HEALTH outcome assessment ,POLYPHENOLS ,PHARMACOLOGY - Abstract
One strategy for understanding variability in attention-deficit hyperactivity disorder (ADHD) medication response, and therefore redressing the current trial-and-error approach to ADHD medication management, is to identify genetic moderators of treatment. This article summarizes ADHD pharmacogenetic investigative efforts to date, which have primarily focused on short-term response to methylphenidate and largely been limited by modest sample sizes. The most well studied genes include the dopamine transporter and dopamine D4 receptor, with additional genes that have been significantly associated with stimulant medication response including the adrenergic a2A-receptor, catechol- O-methyltransferase, D5 receptor, noradrenaline (norepinephrine) transporter protein 1 and synaptosomal-associated protein 25 kDa. Unfortunately, results of current ADHD pharmacogenetic studies have not been entirely consistent, possibly due to differences in study design, medication dosing regimens and outcome measures. Future directions for ADHD pharmacogenetics investigations may include examination of drug-metabolizing enzymes and a wider range of stimulant and non-stimulant medications. In addition, researchers are increasingly interested in going beyond the individual candidate gene approach to investigate gene-gene interactions or pathways, effect modification by additional environmental exposures and whole genome approaches. Advancements in ADHD pharmacogenetics will be facilitated by multi-site collaborations to obtain larger sample sizes using standardized protocols. Although ADHD pharmacogenetic efforts are still in a relatively early stage, their potential clinical applications may include the development of treatment efficacy and adverse effect prediction algorithms that incorporate the interplay of genetic and environmental factors, as well as the development of novel ADHD treatments. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
32. Choline transporter gene variation is associated with attention-deficit hyperactivity disorder.
- Author
-
English, Brett, Hahn, Maureen, Gizer, Ian, Mazei-Robison, Michelle, Steele, Angela, Kurnik, Daniel, Stein, Mark, Waldman, Irwin, and Blakely, Randy
- Abstract
The neurotransmitter acetylcholine (ACh) plays a critical role in brain circuits mediating motor control, attention, learning and memory. Cholinergic dysfunction is associated with multiple brain disorders including Alzheimer’s Disease, addiction, schizophrenia and Attention-Deficit Hyperactivity Disorder (ADHD). The presynaptic choline transporter (CHT, SLC5A7) is the major, rate-limiting determinant of ACh production in the brain and periphery and is consequently upregulated during tasks that require sustained attention. Given the contribution of central cholinergic circuits to the control of movement and attention, we hypothesized that functional CHT gene variants might impact risk for ADHD. We performed a case-control study, followed by family-based association tests on a separate cohort, of two purportedly functional CHT polymorphisms (coding variant Ile89Val (rs1013940) and a genomic SNP 3’ of the CHT gene (rs333229), affording both a replication sample and opportunities to reduce potential population stratification biases. Initial genotyping of pediatric ADHD subjects for two purportedly functional CHT alleles revealed a 2–3 fold elevation of the Val89 allele ( n = 100; P = 0.02) relative to healthy controls, as well as a significant decrease of the 3’SNP minor allele in Caucasian male subjects ( n = 60; P = 0.004). In family based association tests, we found significant overtransmission of the Val89 variant to children with a Combined subtype diagnosis (OR = 3.16; P = 0.01), with an increased Odds Ratio for a haplotype comprising both minor alleles. These studies show evidence of cholinergic deficits in ADHD, particularly for subjects with the Combined subtype, and, if replicated, may encourage further consideration of cholinergic agonist therapy in the disorder. [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
33. Dopamine Transporter Genotype and Methylphenidate Dose Response in Children with ADHD.
- Author
-
Stein, Mark A, Waldman, Irwin D, Sarampote, Christopher S, Seymour, Karen E, Robb, Adelaide S, Conlon, Charles, Soo-jeong Kim, and Cook Jr, Edwin H
- Subjects
- *
DOPAMINE , *ATTENTION-deficit hyperactivity disorder , *GENETIC polymorphisms , *NEUROTRANSMITTERS , *CATECHOLAMINES , *CLINICAL trials - Abstract
Stimulant medications, such as methylphenidate (MPH), are the most commonly used, effective treatment for ADHD. MPH acts primarily by inhibiting the dopamine transporter (DAT), a protein responsible for the reuptake of dopamine from the synapse into presynaptic terminals. We sought to evaluate the relationship between DATI 3'-untranslated region (3'-UTR) variable number tandem repeats (VNTR) genotypes and dose response to MPH. Children with ADHD (n = 47), ages 5-16 years (mean = 9.07 years), underwent a 4-week, double-blinded, crossover trial with forced weekly dosage changes. Children were genotyped for the DATI VNTR and evaluated on placebo and three dosage levels of OROS® MPH. Parents and clinicians who were blind to genotype and medication status rated ADHD symptoms, impairment, and stimulant side effects each week. Children who were homozygous for the less common, 9repeat DATI 3'-UTR genotype displayed a distinct dose-response curve from that of the other genotype groups, with an absence of typical linear improvement when the dose was increased from 18 mg to 36 and 54 mg. Further research is needed to determine the mechanisms related to poor response in patients with the 9/9-repeat genotype, and to determine if this group responds differentially to alternative treatments. [ABSTRACT FROM AUTHOR]
- Published
- 2005
- Full Text
- View/download PDF
34. Clinical immunology in practice, new opportunities.
- Author
-
Stein, Mark
- Abstract
While research provides new opportunities for diagnosing and treating patients with allergic and immunological disorders, there are significant challenges to putting these advances into use in clinical practice. Each new test may require clinicians in private practice to battle with a health insurer's designated clinical laboratory in an effort to get this new test and other accurate immunological laboratory studies. A new test may or may not be covered by some health care plans and may or may not be available from their designated laboratories. Many of these laboratories send time-sensitive samples across the country with risk of time delays and poor specimen handling leading to inaccurate results and/or the need to send repeat specimens. The growing role of managed care in every medical decision has led to frustrations for the patient and physician. This frequently requires a consult at a tertiary care center, where laboratory studies may be more easily accessible with fewer restrictions. Where are the new opportunities? Some are found in the enhanced ability to make intelligent decisions in the diagnosis and treatment of immunological diseases. There is now a greater selection and availability of intravenous γ-globulin (IVIG), that can be matched to individual patient needs. The appropriate selection of these products will decrease adverse reactions and increase safety. There was a major advance in the treatment of moderate and severe asthma with the addition of omalizumab therapy. It provides allergists and immunologists with their first monoclonal humanized anti-IgE antibody. [ABSTRACT FROM AUTHOR]
- Published
- 2004
- Full Text
- View/download PDF
35. Dexmethylphenidate: A Viewpoint by Mark A. Stein.
- Author
-
Stein, Mark A.
- Subjects
- *
STIMULANTS , *PHARMACOLOGY , *TREATMENT of attention-deficit hyperactivity disorder - Abstract
Discusses the pharmacological action of stimulant dexmethylphenidate in the treatment of attention deficit hyperactivity disorder. Ability to increase dopamine levels in the striatum; Adverse effects of stimulant; Duration of action of stimulants.
- Published
- 2002
- Full Text
- View/download PDF
36. Cigarette Smoking Among Youth with Attention-Deficit/Hyperactivity Disorder: Clinical Phenomenology, Comorbidity, and Genetics.
- Author
-
Tercyak, Kenneth P., Peshkin, Beth N., Walker, Leslie R., and Stein, Mark A.
- Subjects
SMOKING ,CIGARETTE smokers ,ATTENTION-deficit hyperactivity disorder ,TOBACCO ,SMOKABLE plants ,BEHAVIOR disorders in children - Abstract
Cigarette smoking and other forms of tobacco use among children and adolescents is a significant public health concern. The negative consequences of prolonged exposure to such substances are numerous, and include higher prevalence rates of cardiopulmonary dysfunction and certain cancers, and may lead to other forms of drug use. Identifying subgroups of youth who may be at greater risk than others to develop a nicotine habit is an important step forward in preventing smoking initiation, and controlling tobacco use. One such subgroup is children with attention-deficit/hyperactivity disorder (ADHD). This is because the prevalence of smoking among these youngsters is nearly twice as high as it is among those who are unaffected with ADHD. However, the etiology of this association is not known. It is possible that a constellation of social, behavioral, and biological factors influences this process, resulting in higher prevalence rates. To further our understanding of this problem, we reviewed each of these factors in relationship to smoking and to ADHD. Using the primary care population as a model, we then discuss clinical research methods that may shed additional light on this topic, as well as the strengths and limitations of current smoking prevention and cessation options for ADHD-affected youth who are assessed and treated in medical settings. [ABSTRACT FROM AUTHOR]
- Published
- 2002
- Full Text
- View/download PDF
37. Psychometric properties of the Children's Atypical Development Scale.
- Author
-
Stein, Mark A. and Szumowski, Emily
- Subjects
- *
PSYCHOMETRICS , *BEHAVIOR disorders in children - Abstract
Examines the psychometric properties of the Children's Atypical Development Scale (CADS). Internal consistency and temporal stability; Assessment of pervasive developmental disorder and neurobehavioral disorders.
- Published
- 1994
- Full Text
- View/download PDF
38. Esophageal Stricture Complicating Stevens-Johnson Syndrome.
- Author
-
Stein, Mark R., Thompson, Carlton K., Sawicki, John E., and Martel, Anthony J.
- Subjects
VISION disorders ,BLIND people ,DEGLUTITION disorders ,PATIENTS ,RADIOLOGY - Abstract
Esophageal stricture may occur as a late complication of the Stevens-Johnson syndrome. Our patient suffered multiple complications, including bilateral blindness and developed significant dysphagia two months after the onset of the Stevens-Johnson syndrome. Early radiologic and endoscopic documentation of the stricture of the distal esophagus led to the initiation of treatment with esophageal dilatation. A program of esophageal dilatation and antacid therapy was successful in relieving the dysphagia and in returning the patient to her normal diet. With early diagnosis and treatment of esophageal stricture surgical intervention may be avoided. [ABSTRACT FROM AUTHOR]
- Published
- 1974
39. Consensus Statement on ADHD.
- Author
-
Barkley, Russell A., Cook, Edwin H., Dulcan, Mina, Campbell, Susan, Prior, Margot, Atkings, Marc, Gillberg, Christopher, Solanto-Gardner, Mark, Halperin, Jeffrey, Bauermeister, Jose J., Pliszka, Steven R., Stein, Mark A., Werry, John S., Sergeant, Joseph, Brown, Ronald T., Zametkin, Alan, Anastopoulos, Arthur D., McGough, James J., and DuPaul, George J.
- Subjects
ATTENTION-deficit hyperactivity disorder ,BEHAVIOR disorders in children - Abstract
Relates the concerns of international scientists over the inaccuracy of media reports concerning attention deficit hyperactivity disorder (ADHD). Views of non-expert doctors on ADHD; Recognition given by health agencies to ADHD; Way in which the media could help ADHD patients.
- Published
- 2002
- Full Text
- View/download PDF
40. Response to the Letter to the Editor Regarding 'Assessment of Local Adverse Reactions to Subcutaneous Immunoglobulin (SCIG) in Clinical Trials'.
- Author
-
Suez, Daniel, Stein, Mark, Gupta, Sudhir, Hussain, Iftikhar, Melamed, Isaac, Paris, Kenneth, Darter, Amy, Bourgeois, Christelle, Fritsch, Sandor, Leibl, Heinz, McCoy, Barbara, Gelmont, David, and Yel, Leman
- Subjects
- *
DRUG side effects , *THERAPEUTIC use of immunoglobulins , *CLINICAL trials - Published
- 2017
- Full Text
- View/download PDF
41. Erratum to: Evaluation of the Safety, Tolerability, and Pharmacokinetics of Gammaplex® 10% Versus Gammaplex® 5% in Subjects with Primary Immunodeficiency.
- Author
-
Wasserman, Richard, Melamed, Isaac, Stein, Mark, Jolles, Stephen, Norton, Miranda, and Moy, James
- Subjects
INTRAVENOUS immunoglobulins ,IMMUNODEFICIENCY ,PHARMACOKINETICS - Published
- 2017
- Full Text
- View/download PDF
42. Erratum to: Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: a randomized phase II trial by the prostate cancer clinical trials consortium.
- Author
-
Bradley, Deborah, Daignault, Stephanie, Ryan, Charles, DiPaola, Robert, Cooney, Kathleen, Smith, David, Small, Eric, Mathew, Paul, Gross, Mitchell, Stein, Mark, Chen, Alice, Pienta, Kenneth, Escara-Wilke, June, Doyle, Gerald, Al-Hawary, Mahmoud, Keller, Evan, and Hussain, Maha
- Published
- 2011
- Full Text
- View/download PDF
43. SNP genotyping using TaqMan® technology: the CYP2D6*17 assay conundrum.
- Author
-
Gaedigk, Andrea, Freeman, Natalie, Hartshorne, Toinette, Riffel, Amanda K., Irwin, David, Bishop, Jeffrey R., Stein, Mark A., Newcorn, Jeffrey H., Jaime, Lazara Karelia Montané, Cherner, Mariana, and Leeder, J. Steven
- Subjects
GENOTYPES ,PHENOTYPES ,GENOMES ,GENETICS ,METABOLISM - Abstract
CYP2D6 contributes to the metabolism of many clinically used drugs and is increasingly tested to individualize drug therapy. The CYP2D6 gene is challenging to genotype due to the highly complex nature of its gene locus. TaqMan® technology is widely used in the clinical and research settings for genotype analysis due to assay reliability, low cost, and the availability of commercially available assays. The assay identifying 1023C>T (rs28371706) defining a reduced function (CYP2D6*17) and several nonfunctional alleles, produced a small number of unexpected diplotype calls in three independent sets of samples, i.e. calls suggested the presence of a CYP2D6*4 subvariant containing 1023C>T. Gene resequencing did not reveal any unknown SNPs in the primer or probe binding sites in any of the samples, but all affected samples featured a trio of SNPs on their CYP2D6*4 allele between one of the PCR primer and probe binding sites. While the phenomenon was ultimately overcome by an alternate assay utilizing a PCR primer excluding the SNP trio, the mechanism causing this phenomenon remains elusive. This rare and unexpected event underscores the importance of assay validation in samples representing a variety of genotypes, but also vigilance of assay performance in highly polymorphic genes such as CYP2D6. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
44. Sleep and emotional reactivity to extended release dexmethylphenidate versus mixed amphetamine salts: a double-blind, placebo controlled study.
- Author
-
Wiebe, Sabrina, Gruber, Reut, Charney, Elizabeth, Aryal, Subhash, Waldman, Irwin, Newcorn, Jeffrey, and Stein, Mark
- Abstract
Introduction and objective: Attention-deficit/hyperactivity disorder (ADHD) is a common childhood disorder. Children with ADHD often display sleep problems and mood instability, which are exacerbated with stimulant medication. This study examined the relationship between sleep and emotional reactivity to dexmethlyphenidate (DMPH) and mixed amphetamine salts (MAS). Methods: Forty children, aged 9–17, participated in a double-blind crossover study comparing two stimulants (extended release DMPH, MAS) at three doses (10, 20, 25–30 mg), with two randomized placebo periods. Treatments lasted 1 week. Sleep and emotional reactivity were assessed using actigraphy and questionnaires. Results: Higher dosages reduced sleep duration, regardless of medication. Sleep was differentially related to emotional reactivity across medications, with later wake time being correlated with decreased depression, anger and anxiety scores during DMPH treatment, while no consistent relationship was found for MAS. Discussion: Although sleep deteriorated with dosage, later wake times were associated with less negative emotionality for DMPH, suggesting improved sleep may prove particularly beneficial with this stimulant. Conclusion: The relationship between sleep and emotionality suggests a need for combined sleep and stimulant treatment to increase tolerability and treatment compliance. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
45. The war on ADHD.
- Author
-
Stein, Mark
- Subjects
- *
ATTENTION-deficit hyperactivity disorder , *NONFICTION - Abstract
The article reviews the book "Hyperactive: The Controversial History of ADHD" by Matthew Smith.
- Published
- 2013
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.